General Information of Drug (ID: DMIUFS4)

Drug Name
GI 181771 Drug Info
Synonyms
GI 181771; GI-181771X; UNII-6YF0SHR37T; 305366-98-7; 6YF0SHR37T; CHEMBL1269257; GSKI181771X; GSKI 181771X; DTXSID60184613; BDBM50329178; DB12309; SB18866; HY-11076; GI-181771; CS-0003036; J3.552.309J; (S)-3-(3-(1-(2-(isopropyl(phenyl)amino)-2-oxoethyl)-2,4-dioxo-5-phenyl-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepin-3-yl)ureido)benzoic acid; 782482-04-6
Indication
Disease Entry ICD 11 Status REF
Obesity 5B81 Discontinued in Phase 2 [1]
Cross-matching ID
PubChem CID
51353551
CAS Number
CAS 305366-98-7
TTD Drug ID
DMIUFS4

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dexloxiglumide DM52HUD Pancreatic malfunction DC30-DC3Z Phase 2 [3]
proglumide DM4MF9V Influenza virus infection 1E30-1E32 Phase 2 [4]
Lintitript DMS5X94 Obesity 5B81 Discontinued in Phase 2 [5]
Tarazepide DMX6ZYE Gastrointestinal disease DE2Z Discontinued in Phase 2 [6]
Pranazepide DMP43IR Pancreatic malfunction DC30-DC3Z Discontinued in Phase 2 [7]
CE-326597 DMXO49B Obesity 5B81 Discontinued in Phase 2 [8]
UCL-2000; butabindide DML51D0 Obesity 5B81 Discontinued in Phase 1 [9]
SSR-125180 DMSOBW2 Obesity 5B81 Discontinued in Phase 1 [10]
T-0632 DML4M5K Pancreatic malfunction DC30-DC3Z Discontinued in Phase 1 [11]
SR-146131 DML7KCO Obesity 5B81 Discontinued in Phase 1 [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cholecystokinin receptor type A (CCKAR) TTCG0AL CCKAR_HUMAN Agonist [2]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013294)
2 Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2003 Jul-Aug;25(6):483-506.
3 Full agonists of CCK8 containing a nonhydrolyzable sulfated tyrosine residue. J Med Chem. 1989 Feb;32(2):445-9.
4 Pharmacological properties of lorglumide as a member of a new class of cholecystokinin antagonists. Arzneimittelforschung. 1987 Nov;37(11):1265-8.
5 A cholecystokinin-1 receptor agonist (CCK-8) mediates increased permeability of brain barriers to leptin. Br J Pharmacol. 2008 Jul;154(5):1009-15.
6 Melatonin as modulator of pancreatic enzyme secretion and pancreatoprotector. J Physiol Pharmacol. 2007 Dec;58 Suppl 6:65-80.
7 Dual CCK-A and -B receptor antagonists (I) C9-methyl-1,4-benzodiazepines, Bioorg. Med. Chem. Lett. 7(2):169-174 (1997).
8 Obesity Pharmacotherapy: Current Perspectives and Future Directions. Curr Cardiol Rev. 2013 February; 9(1): 33-54.
9 Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
10 US patent application no. 8,748,419, Antagonists.
11 Effect of T-0632, a cholecystokininA receptor antagonist, on experimental acute pancreatitis. Jpn J Pharmacol. 1997 Feb;73(2):105-12.
12 SR146131: a new potent, orally active, and selective nonpeptide cholecystokinin subtype 1 receptor agonist. I. In vitro studies. J Pharmacol Exp Ther. 1999 May;289(2):742-51.